Standard BioTools Completes $425M Sale of SomaLogic to Illumina

Deal includes $350M upfront cash, up to $75M in earnout payments, and royalties on future sales.

Jan. 30, 2026 at 8:31am

Got story updates? Submit your updates here. ›

Standard BioTools Inc. has completed the sale of its SomaLogic business unit to Illumina, Inc. for $350 million in upfront cash and up to $75 million in additional earnout payments, for a total potential consideration of $425 million. The deal also includes a 2% royalty on net revenues from sales of SOMAmer-based NGS library preparation kits for 10 years, as well as a co-exclusive license to the intellectual property relating to Single SOMAmer commercialization.

Why it matters

The sale of SomaLogic allows Standard BioTools to focus on its core business and pursue a disciplined M&A strategy to drive growth and scale. With an estimated $550 million in cash and cash equivalents on its balance sheet after the deal, the company is well-positioned to make strategic acquisitions to expand its portfolio of essential next-generation technologies for biomedical research.

The details

Under the terms of the agreement, Standard BioTools received $350 million in upfront cash at closing, and is eligible for up to $75 million in additional earnout payments based on the performance of the SomaLogic business in 2025 and 2026. The company will also receive a 2% royalty on net revenues generated from sales of SOMAmer-based NGS library preparation kits for 10 years, as well as a co-exclusive license to the intellectual property relating to Single SOMAmer commercialization.

  • The transaction closed on January 30, 2026.

The players

Standard BioTools Inc.

A leading provider of essential, standardized next-generation technologies for biomedical research, including mass cytometry and microfluidics technologies.

Illumina, Inc.

A global leader in DNA sequencing and array-based technologies, which has acquired the SomaLogic business unit from Standard BioTools.

Michael Egholm, PhD

President and Chief Executive Officer of Standard BioTools.

Got photos? Submit your photos here. ›

What they’re saying

“The closing of this transaction marks a major milestone in our strategic transformation. We are lean, focused and extremely well positioned, and emerge today far stronger than we were yesterday.”

— Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools (Globe Newswire)

What’s next

Standard BioTools plans to use the proceeds from the sale to fuel its inorganic growth strategy, including pursuing disciplined M&A to accelerate growth and scale.

The takeaway

The sale of SomaLogic to Illumina allows Standard BioTools to streamline its focus and financial resources, positioning the company to make strategic acquisitions and investments to expand its portfolio of essential technologies for biomedical research.